{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:58:28Z","timestamp":1790812708309,"version":"4.1.0"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pancreas"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Pancreatic cancer is the third leading cause of cancer death in the United States, with projections that it will become the second leading cause by the year 2030. It carries a dismal prognosis with a 5-year overall survival rate of less than 9% and is associated with numerous comorbidities, the most notable being cachexia. Defined as the loss of muscle mass not reversible by conventional nutritional support, cachexia is seen in over 85% of pancreatic cancer patients and contributes significantly to mortality, where nearly 30% of pancreatic cancer deaths are due to cachexia rather than tumor burden. Therefore, there is an urgent need to identify the mechanisms behind the development of muscle wasting in pancreatic cancer patients and design novel therapeutics targeting cachexia. This review highlights the current understanding surrounding the mechanisms underpinning the development of cachexia in pancreatic cancer, as well as the current mouse models of pancreatic cancer\u2013induced muscle wasting described in the literature.<\/jats:p>","DOI":"10.1097\/mpa.0000000000001124","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T03:49:22Z","timestamp":1534391362000},"page":"937-945","source":"Crossref","is-referenced-by-count":46,"title":["Pancreatic Cancer\u2013Induced Cachexia and Relevant Mouse Models"],"prefix":"10.1097","volume":"47","author":[{"given":"Sally E.","family":"Henderson","sequence":"first","affiliation":[{"name":"Department of Veterinary Biosciences, College of Veterinary Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Makhijani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Mace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230822","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","year":"2014","journal-title":"Cancer Res"},{"key":"bib2-20230822","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib3-20230822","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3748\/wjg.v19.i6.813","article-title":"Current evidence for histone deacetylase inhibitors in pancreatic cancer","volume":"19","year":"2013","journal-title":"World J Gastroenterol"},{"key":"bib4-20230822","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s11605-011-1665-9","article-title":"Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience","volume":"15","year":"2011","journal-title":"J Gastrointest Surg"},{"key":"bib5-20230822","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/bjc.1997.17","article-title":"Changes in nutritional status associated with unresectable pancreatic cancer","volume":"75","year":"1997","journal-title":"Br J Cancer"},{"key":"bib6-20230822","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling and metabolic pathways","volume":"16","year":"2012","journal-title":"Cell Metab"},{"key":"bib7-20230822","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.advms.2013.11.001","article-title":"Anorexia-cachexia syndrome in pancreatic cancer: recent advances and new pharmacological approach","volume":"59","year":"2014","journal-title":"Adv Med Sci"},{"key":"bib8-20230822","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","year":"2008","journal-title":"Clin Nutr"},{"key":"bib9-20230822","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1471-2407-9-255","article-title":"Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function","volume":"9","year":"2009","journal-title":"BMC Cancer"},{"key":"bib10-20230822","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.lfs.2010.11.011","article-title":"Identification of serum proteins involved in pancreatic cancer cachexia","volume":"88","year":"2011","journal-title":"Life Sci"},{"key":"bib11-20230822","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1158\/0008-5472.CAN-12-4601","article-title":"Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner","volume":"73","year":"2013","journal-title":"Cancer Res"},{"key":"bib12-20230822","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2015.04.003","article-title":"Cachexia and sarcopenia: mechanisms and potential targets for intervention","volume":"22","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"bib13-20230822","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1158\/1078-0432.CCR-05-0185","article-title":"Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia","volume":"11","year":"2005","journal-title":"Clin Cancer Res"},{"key":"bib14-20230822","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11605-013-2168-7","article-title":"Activation of the IL-6R\/Jak\/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma","volume":"17","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"bib15-20230822","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/bjc.2013.174","article-title":"Serum levels of IL-6 and IL-1\u03b2 can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer","volume":"108","year":"2013","journal-title":"Br J Cancer"},{"key":"bib16-20230822","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.imlet.2016.11.010","article-title":"IL-6 roles \u2014 Molecular pathway and clinical implication in pancreatic cancer \u2014 a systemic review","volume":"181","year":"2017","journal-title":"Immunol Lett"},{"key":"bib17-20230822","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-15-1732","article-title":"Systemic immune activity predicts overall survival in treatment-naive patients with metastatic pancreatic cancer","volume":"22","year":"2016","journal-title":"Clin Cancer Res"},{"key":"bib18-20230822","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3748\/wjg.v9.i7.1567","article-title":"Role of NF-kappaB and cytokine in experimental cancer cachexia","volume":"9","year":"2003","journal-title":"World J Gastroenterol"},{"key":"bib19-20230822","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","article-title":"JAK\/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia","volume":"303","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"bib20-20230822","doi-asserted-by":"crossref","first-page":"e22538","DOI":"10.1371\/journal.pone.0022538","article-title":"STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia","volume":"6","year":"2011","journal-title":"PLoS One"},{"key":"bib21-20230822","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1126\/science.289.5488.2363","article-title":"NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia","volume":"289","year":"2000","journal-title":"Science"},{"key":"bib22-20230822","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00432-013-1412-6","article-title":"MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia","volume":"139","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"bib23-20230822","first-page":"805","article-title":"Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia","volume":"22","year":"2007","journal-title":"Histol Histopathol"},{"key":"bib24-20230822","doi-asserted-by":"crossref","first-page":"e0132786","DOI":"10.1371\/journal.pone.0132786","article-title":"TGF-\u03b2 blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"bib25-20230822","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00520-016-3553-z","article-title":"A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients","volume":"25","year":"2017","journal-title":"Support Care Cancer"},{"key":"bib26-20230822","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/1078-0432.CCR-16-0495","article-title":"Molecular pathways: cachexia signaling\u2014a targeted approach to cancer treatment","volume":"22","year":"2016","journal-title":"Clin Cancer Res"},{"key":"bib27-20230822","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member","volume":"387","year":"1997","journal-title":"Nature"},{"key":"bib28-20230822","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/153537020623100507","article-title":"Activin signaling and its role in regulation of cell proliferation, apoptosis and carcinogenesis","volume":"231","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"key":"bib29-20230822","doi-asserted-by":"crossref","first-page":"C1248","DOI":"10.1152\/ajpcell.00104.2009","article-title":"Smad2 and 3 transcription factors control muscle mass in adulthood","volume":"296","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"bib30-20230822","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1210\/jc.2014-4318","article-title":"Role of Activin A and myostatin in human cancer cachexia","volume":"100","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"bib31-20230822","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","year":"2010","journal-title":"Cell"},{"key":"bib32-20230822","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.canlet.2014.10.037","article-title":"Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer","volume":"356","year":"2015","journal-title":"Cancer Lett"},{"key":"bib33-20230822","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-007-0177-2","article-title":"Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia","volume":"85","year":"2007","journal-title":"J Mol Med (Berl)"},{"key":"bib34-20230822","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/onc.2008.21","article-title":"The FoxO code","volume":"27","year":"2008","journal-title":"Oncogene"},{"key":"bib35-20230822","doi-asserted-by":"crossref","first-page":"e108057","DOI":"10.1371\/journal.pone.0108057","article-title":"AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"bib36-20230822","doi-asserted-by":"crossref","first-page":"E591","DOI":"10.1152\/ajpendo.00073.2004","article-title":"IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1","volume":"287","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"bib37-20230822","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brainres.2005.03.011","article-title":"The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway","volume":"1044","year":"2005","journal-title":"Brain Res"},{"key":"bib38-20230822","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbrc.2005.10.182","article-title":"Apolipoprotein C-II is a novel substrate for matrix metalloproteinases","volume":"339","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"bib39-20230822","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bbalip.2003.12.004","article-title":"Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein","volume":"1636","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"bib40-20230822","first-page":"157","article-title":"Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management","volume":"7","year":"2006","journal-title":"JOP"},{"key":"bib41-20230822","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/01.mco.0000134363.53782.cb","article-title":"Cancer anorexia-cachexia syndrome: cytokines and neuropeptides","volume":"7","year":"2004","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"bib42-20230822","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12885-016-2121-8","article-title":"Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia\u2014can findings from animal models be translated to humans?","volume":"16","year":"2016","journal-title":"BMC Cancer"},{"key":"bib43-20230822","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"bib44-20230822","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.18632\/oncotarget.13593","article-title":"Human pancreatic cancer xenografts recapitulate key aspects of cancer cachexia","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib45-20230822","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2049-3002-2-18","article-title":"Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia","volume":"2","year":"2014","journal-title":"Cancer Metab"},{"key":"bib46-20230822","article-title":"Orthotopic model of human pancreatic ductal adenocarcinoma and cancer cachexia in nude mice","year":"2007","journal-title":"Curr Protoc Pharmacol"},{"key":"bib47-20230822","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3748\/wjg.v18.i22.2867","article-title":"Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts","volume":"18","year":"2012","journal-title":"World J Gastroenterol"},{"key":"bib48-20230822","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/jcp.24580","article-title":"Pancreatic cancer-induced cachexia is Jak2-dependent in mice","volume":"229","year":"2014","journal-title":"J Cell Physiol"},{"key":"bib49-20230822","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.neo.2016.10.003","article-title":"Suppression of tumor growth and muscle wasting in a transgenic mouse model of pancreatic cancer by the novel histone deacetylase inhibitor AR-42","volume":"18","year":"2016","journal-title":"Neoplasia"},{"key":"bib50-20230822","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.neo.7900005","article-title":"In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice","volume":"1","year":"1999","journal-title":"Neoplasia"},{"key":"bib51-20230822","doi-asserted-by":"crossref","first-page":"41146","DOI":"10.18632\/oncotarget.5843","article-title":"Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth","volume":"6","year":"2015","journal-title":"Oncotarget"},{"key":"bib52-20230822","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1593\/neo.81582","article-title":"Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma","volume":"11","year":"2009","journal-title":"Neoplasia"},{"key":"bib53-20230822","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/JTO.0b013e31819c791a","article-title":"INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma","volume":"4","year":"2009","journal-title":"J Thorac Oncol"},{"key":"bib54-20230822","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12032-010-9766-y","article-title":"Upregulated INHBA expression is associated with poor survival in gastric cancer","volume":"29","year":"2012","journal-title":"Med Oncol"},{"key":"bib55-20230822","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","year":"2005","journal-title":"Cancer Cell"},{"key":"bib56-20230822","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.4049\/jimmunol.171.6.3034","article-title":"Characterization of the CD200 receptor family in mice and humans and their interactions with CD200","volume":"171","year":"2003","journal-title":"J Immunol"},{"key":"bib57-20230822","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/onc.2016.378","article-title":"TGF\u03b2 promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1","volume":"36","year":"2017","journal-title":"Oncogene"},{"key":"bib58-20230822","doi-asserted-by":"crossref","first-page":"djv274","DOI":"10.1093\/jnci\/djv274","article-title":"Preclinical investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced cachexia","volume":"107","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"bib59-20230822","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MPA.0b013e3181c15619","article-title":"Modeling pancreatic cancer in vivo: from xenograft and carcinogen-induced systems to genetically engineered mice","volume":"39","year":"2010","journal-title":"Pancreas"},{"key":"bib60-20230822","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/MPA.0000000000000843","article-title":"Orthotopic patient-derived pancreatic cancer xenografts engraft into the pancreatic parenchyma, metastasize, and induce muscle wasting to recapitulate the human disease","volume":"46","year":"2017","journal-title":"Pancreas"},{"key":"bib61-20230822","doi-asserted-by":"crossref","first-page":"e77065","DOI":"10.1371\/journal.pone.0077065","article-title":"Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"bib62-20230822","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ajpath.2015.01.016","article-title":"Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements","volume":"185","year":"2015","journal-title":"Am J Pathol"},{"key":"bib63-20230822","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/MPA.0b013e318279b87f","article-title":"Disrupting cytokine signaling in pancreatic cancer: a phase I\/II study of etanercept in combination with gemcitabine in patients with advanced disease","volume":"42","year":"2013","journal-title":"Pancreas"},{"key":"bib64-20230822","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","article-title":"Role of interleukin-6 in cachexia: therapeutic implications","volume":"8","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"key":"bib65-20230822","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","year":"2016","journal-title":"Cell Metab"},{"key":"bib66-20230822","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1245\/s10434-012-2225-6","article-title":"Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice?","volume":"19","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"bib67-20230822","first-page":"166","article-title":"Feeding challenges in patients with esophageal and gastroesophageal cancers","volume":"2","year":"2016","journal-title":"Gastrointest Tumors"},{"key":"bib68-20230822","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdu085","article-title":"Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force","volume":"25","year":"2014","journal-title":"Ann Oncol"},{"key":"bib69-20230822","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia","volume":"89","year":"2009","journal-title":"Physiol Rev"},{"key":"bib70-20230822","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1097\/MPA.0000000000000898","article-title":"Predictors of pancreatic cancer-associated weight loss and nutritional interventions","volume":"46","year":"2017","journal-title":"Pancreas"},{"key":"bib71-20230822","first-page":"629","article-title":"Systemic inflammation in cachexia \u2014 is tumor cytokine expression profile the culprit?","volume":"6","year":"2015","journal-title":"Front Immunol"},{"key":"bib72-20230822","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcsm.12037","article-title":"Cachexia-associated adipose tissue morphological rearrangement in gastrointestinal cancer patients","volume":"7","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"bib73-20230822","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6603360","article-title":"Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice","volume":"95","year":"2006","journal-title":"Br J Cancer"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006676-201809000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:01:41Z","timestamp":1692709301000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-201809000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000001124","relation":{},"ISSN":["1536-4828","0885-3177"],"issn-type":[{"value":"1536-4828","type":"electronic"},{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}